In cutaneous melanoma, inhibitors of the BRAF (BRAFi) and MEK (MEKi) kinases (e.g., vemurafenib and cobimetinib) are prototypical of highly effective targeted anti‐cancer drugs (English & Cobb, 2002; Samatar & Poulikakos, 2014). Here, MAP2K7 is linked to cancer.